Ph Health Patent-Cliff Exposure & CMS Drug Spending Portfolio

Ph Health (US): 13 reconciled FDA prescription therapies, $29.5M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies13
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2035-01-01
2024 CMS Total Public Spend$29.5M
2024 Medicare Part D Spend$9.1M
2024 Medicaid Spend$20.4M
California HCAI SB 17 Filings8 WAC filings (max 50.0% 2-yr change)